Shaun Rosebeck
ORCID：0000-0003-1781-4601
发表论文 47 篇 · 总被引 731 次 · h-index 13
代表论文
- Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma (2019 · British Journal of Haematology · 被引 69)
- Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) (2016 · Blood · 被引 45)
- Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models (2019 · Cancer Medicine · 被引 20)
- Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells (2016 · Blood Cancer Journal · 被引 19)
- Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) (2016 · Blood · 被引 13)
- High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial (2017 · Blood · 被引 10)